Opinion|Videos|January 23, 2025 (Updated: January 23, 2025)
Abiraterone Acetate Versions for Treatment of mCRPC
Author(s)Jose De La Cerda III, MD, MPH
This video segment explores how to choose between the original brand, generic, and micronized versions of abiraterone, considering factors like efficacy, cost, patient preference, and clinical context.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Abiraterone is now available as the original brand, generic and micronized versions. How do you choose between these different options of abiraterone?
Advertisement
Related to this article
Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.
The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.
Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
Heather Florio joins to discuss the potential role of supplements in pelvic and sexual health.
John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.
A recap of the FDA submissions and regulatory decisions in urology from September 2026.
Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: Key Updates to the AUA NMIBC Guideline, With Peter E. Clark, MD
2
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
3
FDA updates in urology: September 2026
4
Aglatimagene besadenovec shows sustained immune remodeling in localized prostate cancer
5